Results 321 to 330 of about 656,371 (370)
Some of the next articles are maybe not open access.
Minimal residual disease in gastrointestinal cancer
Seminars in Surgical Oncology, 2001AbstractTumor progression after curative resection of gastrointestinal carcinomas is probably caused by pre‐ or intraoperative tumor cell dissemination. Disseminated tumor cells are generally detected by immunohistochemistry‐ or PCR‐based molecular‐biology methods. A consensus on which is the most adequate detection method has not yet been found, which
Moritz Koch, Peter Kienle
openaire +3 more sources
Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach
Current Protocols in Cytometry, 2020The identification of residual leukemia following therapy, termed minimal or measurable residual disease (MRD), has emerged as one of the most important prognostic factors for patients with acute leukemia, including acute myeloid leukemia (AML).
B. Wood
semanticscholar +1 more source
[Minimal residual disease in AML].
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2020Minimal (measurable) residual disease (MRD) in acute leukemia denotes the presence of leukemic cells detected by multiparameter flow cytometry or various molecular techniques in patients achieving hematological remission. The MRD become an independent, post-diagnosis, prognostic indicator important for risk stratification and treatment planning, in ...
openaire +3 more sources
Techniques for Detection of Minimal Residual Disease
Leukemia & Lymphoma, 1995Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characterized by advantages and limitations,
G. P. Dotti +3 more
openaire +3 more sources
Characterization of Minimal Residual Disease
Blood, 2015Abstract Minimal residual disease (MRD) defines persistence of minimal numbers (<10-2-10-6) of residual tumor cells after treatment. In recent years, evaluation of MRD has become more frequently used as a mean to assess the quality of response to therapy in multiple myeloma (MM), particularly among those patients who have reached ...
Jesús F. San Miguel +8 more
openaire +2 more sources
Markers of Minimal Residual Disease
1982Current methods employing tumour markers to detect small amounts of residual disease are reviewed with respect to human germ cell, colorectal and breast neoplasms. It is concluded that the assay of tumour markers in body fluids has only limited clinical value. Alternative approaches, such as are afforded by radioimmunodetection and immunocytochemistry,
openaire +3 more sources
Managing Minimal Residual Malignant Disease
Oncology, 1986So-called complete remission of acute leukemia and other tumors frequently leaves minimal residual disease cells, sometimes causing an inflammatory response and often relapse. Although the remaining cells often have long generation times or may even be in G0 condition, they may form a new tumor mass.
G. Mathé, P. Reizenstein
openaire +3 more sources
Minimal residual disease in thyroid carcinoma
Seminars in Surgical Oncology, 2001AbstractThe detection of disseminated tumor cells in differentiated (DTC) and medullary thyroid carcinomas (MTC) is one of the main topics in current thyroid cancer research. Immunocytochemistry and polymerase chain reaction (PCR) provide the tools for the identification of a small number of thyroid cancer cells in peripheral blood and cervical lymph ...
Ernst Klar, Theresia Weber
openaire +3 more sources
Minimal Residual Disease in APL
2018The genetic hallmark of acute promyelocytic leukemia (APL) is the balanced reciprocal translocation t(15;17)(q22;q11–12) leading to a fusion of the promyelocytic leukemia (PML) and the retinoic acid receptor alpha (RARA) gene. The fusion gene results in a chimeric PML-RARA oncoprotein which plays a causative role in APL pathogenesis [1].
Eva Barragán, Laura Cicconi
openaire +2 more sources
Kinetics of Minimal Residual Disease
1979The development of a rational approach to adjuvant chemotherapy of cancer depends upon at least four factors: 1. Recognition that micrometastases are frequently disseminated and established prior to the time of surgery for a primary cancer; 2.
openaire +3 more sources